The Diagnosis and Treatment of Catatonia in Individuals with Profound Autism belongs in serious BCBA study because it shapes whether behavior-analytic decisions stay useful once they leave a clean training example and enter case conceptualization, intervention design, staff training, and literature-informed problem solving. In Profound Autism on The Diagnosis and Treatment of Catatonia in Individuals, for this course, the practical stakes show up in stronger conceptual consistency and better translational decision making, not in abstract discussion alone.
Provider: BehaviorLive — via Profound Autism Summit
Take This Course →Including ethics, supervision, and topics like this one. New live CEU every Wednesday.
Join Free →The effectiveness of the lorazepam challenge test in pediatric catatonia Catatonia is a neuropsychiatric disorder associated with changes in behavior and affect. Dr. Luccarelli reports on a study about the effect of the drug lorazepam on the severity of catatonia as measured by the Bush Francis Catatonia Rating Scale (BFCRS) in pediatric patients. Longitudinal Symptom Burden and Pharmacologic Management of Catatonia in Autism with and without Profound Impairment: An Observational Study Dr. Smith describes his longitudinal observational study of how catatonic symptoms responded to treatment over a three-year period. Genetic Variants in Catatonia Catatonia occurs at high rates in both idiopathic and syndromic disorders. We conducted a retrospective chart review of 48 patients with a neurodevelopmental diagnosis and co-occurring catatonia, and noted that 75% had genetic testing as part of their workup. Testing identified a pathogenic or likely pathogenic variant in 42% of the patients, variants of uncertain significance in 25%, and negative in 33% of patients. Most of the genetic variants found in this cohort were related to GABA or glutamatergic signaling, which have been implicated in the development of catatonia.
| Certification Body | Credits | Type |
|---|---|---|
| BACB® | 1 | General |
| COA | 1 | — |
| NASW | 1 | — |
| PSY | 1 | — |
James Luccarelli is a child, adolescent, and adult psychiatrist at the Massachusetts General Hospital, where he is Director of Pediatric Neurotherapeutics. He is additionally an Instructor in Psychiatry at Harvard Medical School. His research, funded by grants from government, institutional, and philanthropic sources, focuses on the diagnosis and treatment of the neuropsychiatric condition catatonia.
Dig into the research behind this topic — plain-English summaries written for BCBAs.
279 research articles with practitioner takeaways
258 research articles with practitioner takeaways
252 research articles with practitioner takeaways
You earn CEUs from a dozen different places. Upload any certificate — from here, your employer, conferences, wherever — and always know exactly where you stand. Learning, Ethics, Supervision, all handled.
No credit card required. Cancel anytime.
All behavior-analytic intervention is individualized. The information on this page is for educational purposes and does not constitute clinical advice. Treatment decisions should be informed by the best available published research, individualized assessment, and obtained with the informed consent of the client or their legal guardian. Behavior analysts are responsible for practicing within the boundaries of their competence and adhering to the BACB Ethics Code for Behavior Analysts.